| 1 |
Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79: 1283-316
PUBMED
ScienceOn
|
| 2 |
Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C. The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol 2008;87:1-10
PUBMED
|
| 3 |
Fletcher S, Bain B. Eosinophilic leukaemia. Br Med Bull 2007;81:115-27
DOI
ScienceOn
|
| 4 |
Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093-6
DOI
ScienceOn
|
| 5 |
Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-7
DOI
ScienceOn
|
| 6 |
Matsushima T, Handa H, Yokohama A, Nagasaki J, Koiso H, Kin Y, et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 2003;101:3386-90
DOI
ScienceOn
|
| 7 |
Shorr AF, Scoville SL, Cersovsky SB, Shanks GD, Ockenhouse CF, Smoak BL, et al. Acute eosinophilic pneumonia among US Military personnel deployed in or near Iraq. JAMA 2004;292:2997-3005
DOI
ScienceOn
|
| 8 |
Anagnostopoulos GK, Sakorafas GH, Kostopoulos P, Margantinis G, Tsiakos S, Terpos E, et al. Disseminated colon cancer with severe peripheral blood eosinophilia and elevated serum levels of interleukine-2, interleukine-3, interleukine-5, and GM-CSF. J Surg Oncol 2005;89:273-5
DOI
ScienceOn
|
| 9 |
Kawada Y, Yamamoto Y, Noda M, Asayama K, Shirahata A. High prevalence of eosinophilia in growth hormone- deficient children. Pediatr Int 2001;43:141-5
DOI
ScienceOn
|
| 10 |
Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358:1215-28
DOI
ScienceOn
|
| 11 |
Hollman SM, Gallin JI. Disorders of granulocytes and monocytes. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrisons principles of internal medicine. 16th ed. New York: McGraw-Hill Co, 2005:349-57
|
| 12 |
Wardraw A. Eosinophils and their disorders. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams Hematology. 7th ed. New York: McGraw-Hill Co, 2006:863-78
|
| 13 |
Baxter EJ, Kulkarni S, Vizmanos JL, Jaju R, Martinelli G, Testoni N, et al. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br J Haematol 2003;120:251-6
DOI
PUBMED
ScienceOn
|
| 14 |
Bain BJ, Fletcher SH. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am 2007;27:377-88
DOI
ScienceOn
|
| 15 |
B hm A, Fdinger M, Wimazal F, Haas OA, Mayerhofer M, Sperr WR, et al. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol 2007;120:192-9
DOI
ScienceOn
|
| 16 |
Wang LN, Pan Q, Fu JF, Shi JY, Jin J, Li JM, et al. FIP1L1- PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. Chin Med J 2008;121:867-73
PUBMED
ScienceOn
|
| 17 |
Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006;133:468-92
DOI
ScienceOn
|
| 18 |
Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, Castells M, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-53
DOI
ScienceOn
|
| 19 |
Wimazal F, Baumgartner C, Sonneck K, Zauner C, Geissler P, Schur S, et al. Mixed-lineage eosinophil/basophil crisis in MDS: a rare form of progression. Eur J Clin Invest 2008;38:447-55
DOI
ScienceOn
|
| 20 |
Kalac M, Quintás-Cardama A, Vrhovac R, Kantarjian H, Verstovsek S. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer 2007;110:955-64
DOI
ScienceOn
|
| 21 |
Bakhshi S, Hamre M, Mohamed AN, Feldman G, Ravindranath Y. t(5;9)(q11;q34): a novel familial translocation involving Abelson oncogene and association with hypereosinophilia. J Pediatr Hematol Oncol 2003;25:82-4
DOI
ScienceOn
|
| 22 |
Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol 2005;114:52-60
DOI
PUBMED
ScienceOn
|
| 23 |
Vannucchi AM, Guglielmelli P, Tefferi A Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 2009;59:171-91
DOI
ScienceOn
|
| 24 |
Tefferi A. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clin Proc 2005;80:75-83
DOI
ScienceOn
|
| 25 |
Khan S, Orenstein SR. Eosinophilic gastroenteritis. Gastroenterol Clin North Am 2008;37:333-48
DOI
ScienceOn
|
| 26 |
Sheikh J, Weller PF. Advances in diagnosis and treatment of eosinophilia. Curr Opin Hematol 2009;16:3-8
DOI
ScienceOn
|
webmaster
